Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cretostimogene grenadenorepvec - CG Oncology

Next Previous
X
Search
Drug Profile

Cretostimogene grenadenorepvec - CG Oncology

Alternative Names: CG-0070

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer CG Oncolgy; Lepu Biopharma
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bladder cancer
  • No development reported Solid tumours

Most Recent Events

  • 23 Aug 2024 CG Oncology plans a phase II trial for Bladder cancer (Treatment-naive) (Intravesicular) in September 2024 (NCT06567743)
  • 12 Jun 2024 CG Oncology initiates an expanded-access programme for Bladder cancer in USA (NCT06443944)
  • 24 May 2024 Updated efficacy data from the phase II CORE-001 trial in Bladder cancer released by CG Oncolgy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top